Biocartis Group NV: Biocartis and Amgen sign a RAS Biomarker Testing Collaboration in Europe
(Thomson Reuters ONE) -
PRESS RELEASE: 22 December 2016, 07:00 CET
REGULATED INFORMATION - INSIDE INFORMATION
Biocartis and Amgen sign a RAS Biomarker Testing Collaboration in Europe
Mechelen, Belgium, 22 December 2016 - Biocartis Group NV ('Biocartis'), an
innovative molecular diagnostics company (Euronext Brussels: BCART), today
announced the signing of a new collaboration agreement with Amgen, a leading
biotechnology company. The new agreement, which builds on the existing
collaboration between both companies announced on 3 February 2016[1], aims at
accelerating access to RAS biomarker information in up to 10 European countries.
For metastatic colorectal cancer (mCRC) patients, timely information on the
presence of mutations in the RAS genes (KRAS, NRAS) and BRAF[2] is critical for
treatment selection. Current technologies to assess RAS gene mutational status
used by hospitals are complex to perform and on average, require up to one month
to provide results. In certain countries, RAS testing samples have to be sent
abroad, which further delays results and treatment selection for patients.
Based on the experience from the existing collaboration, Biocartis and Amgen
will now aim to enable several dozen additional selected hospitals in Europe to
accelerate access to RAS biomarker information, from up to one month to same-day
results for mCRC patients, using Biocartis' Idylla(TM) platform and RAS tests.
Biocartis' CE-marked RAS mutations test offering has a turn-around-time of only
two hours with less than two minutes hands-on time. Furthermore, the Idylla(TM)
platform can be operated in any hospital laboratory, independent of hospital
size, available infrastructure and experience level.
Ulrik Cordes, EVP Pharma Collaborations and Companion Diagnostics, commented:
"We are very pleased to have expanded our agreement with Amgen. This strong
partnership will help to further boost the footprint of Idylla(TM) systems in
Europe. Additionally, it is another step towards our ultimate goal of improving
patient access to rapid and reliable biomarker information with the potential to
enable more rapid treatment selection."
The expansion of Biocartis' agreement with Amgen is part of Biocartis' active
partnership strategy for its Idylla(TM) platform, aimed at enabling personalized
medicine for patients across the globe through rapid, highly accurate and easy
to use high precision diagnostic solutions. The collaboration also includes the
possibility to use the Idylla(TM) platform in scientific studies to further
understand the role of biomarkers in clinical practice.
--- END ---
More information:
Renate Degrave
Manager Corporate Communications & Investor Relations
e-mail rdegrave(at)biocartis.com
tel +32 15 631 729
mobile +32 471 53 60 64
About Biocartis
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics
(MDx) company providing next generation diagnostic solutions aimed at improving
clinical practice for the benefit of patients, clinicians, payers and industry.
Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-
result, real-time PCR (Polymerase Chain Reaction) system that offers accurate,
highly reliable molecular information from virtually any biological sample in
virtually any setting. Biocartis launched the Idylla(TM) platform in September
2014. Biocartis is developing and marketing a rapidly expanding test menu
addressing key unmet clinical needs in oncology and infectious diseases. These
areas represent respectively the fastest growing and largest segments of the MDx
market worldwide. Today, Biocartis offers six oncology tests and two infectious
disease tests. More information: www.biocartis.com. Press Photo Library
available here. Follow us on Twitter: (at)Biocartis_.
Certain statements, beliefs and opinions in this press release are forward-
looking, which reflect the Company or, as appropriate, the Company directors'
current expectations and projections concerning future events such as the
Company's results of operations, financial condition, liquidity, performance,
prospects, growth, strategies and the industry in which the Company operates. By
their nature, forward-looking statements involve a number of risks,
uncertainties, assumptions and other factors that could cause actual results or
events to differ materially from those expressed or implied by the forward-
looking statements. These risks, uncertainties, assumptions and factors could
adversely affect the outcome and financial effects of the plans and events
described herein. A multitude of factors including, but not limited to, changes
in demand, competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development. Forward-
looking statements contained in this press release regarding past trends or
activities are not guarantees of future performance and should not be taken as a
representation that such trends or activities will continue in the future. In
addition, even if actual results or developments are consistent with the
forward-looking statements contained in this press release, those results or
developments may not be indicative of results or developments in future periods.
As a result, the Company expressly disclaims any obligation or undertaking to
release any update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or any change in events,
conditions, assumptions or circumstances on which these forward-looking
statements are based. Neither the Company nor its advisers or representatives
nor any of its subsidiary undertakings or any such person's officers or
employees guarantees that the assumptions underlying such forward-looking
statements are free from errors nor does either accept any responsibility for
the future accuracy of the forward-looking statements contained in this press
release or the actual occurrence of the forecasted developments. You should not
place undue reliance on forward-looking statements, which speak only as of the
date of this press release.
--------------------------------------------------------------------------------
[1] The collaboration announced on 3 February 2016 focused on selected reference
hospitals in Brazil, Canada, Colombia, Mexico, Saudi Arabia, Spain and Turkey.
[2] Following the latest clinical practice recommendations of the American
Society of Clinical Oncology (ASCO) and the European Society for Medical
Oncology (ESMO). ASCO: Allegra et al, Extended RAS Gene Mutation Testing in
Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth
Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical
Oncology Provisional Clinical Opinion Update 2015, J Clin Oncol
2016, 34:179-185, http://ascopubs.org/doi/pdf/10.1200/jco.2015.63.9674. See
also http://gicasym.org/asco-updates-guideline-include-testing-new-ras-
mutations. ESMO: Van Cutsem et al, ESMO consensus guidelines for the management
of patients with metastatic colorectal cancer, Annals of Oncology
2016, 8:1386-1422.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biocartis Group NV via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 22.12.2016 - 07:01 Uhr
Sprache: Deutsch
News-ID 514437
Anzahl Zeichen: 8700
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 349 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biocartis Group NV: Biocartis and Amgen sign a RAS Biomarker Testing Collaboration in Europe"
steht unter der journalistisch-redaktionellen Verantwortung von
Biocartis Group NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
